Cambrian Bio
Cambrian Biopharma is a biotechnology research and development firm focused on the biology of aging, also known as geroscience. The company aims to develop therapeutics that address the molecular damage associated with aging and related chronic diseases. By employing a "Distributed R&D Company" model, Cambrian partners with leading academic geroscientists to create new companies, conduct preclinical drug discovery, and manage clinical trials. This collaborative approach allows Cambrian to efficiently translate scientific discoveries into clinical applications, aiming to improve quality of life through proactive interventions. The company has successfully launched ten companies in partnership with prominent geroscientists and maintains relationships with over 100 geroscience-focused laboratories worldwide, facilitating rapid development and deployment of age-related disease therapies.
Oviva Therapeutics is focused on enhancing women's health as they age by developing therapeutics aimed at improving ovarian function. The company engages in biomedical research and clinical development to create effective treatments that address female physiology, particularly concerning ovarian aging. In addition to its research initiatives, Oviva Therapeutics advocates for better awareness and understanding of women's health issues. By collaborating with scientists and clinicians, the company aims to drive meaningful advancements in the field, ultimately improving the overall experience of aging for women.
Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita works towards delivering tissue-specific stem cells that have the capability to continue to replicate and support muscle regeneration. The company's lead therapy, VTA-110, is a potential allogenic iPSC-based therapy that has shown the ability to repair and regenerate healthy muscle in preclinical studies and has the potential to benefit patients with LGMD and other muscular dystrophies.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.